Arthur Williams, DO
Family Medicine · Franklin, TNNPI 1760591788
Payments from drug & device makers
Across 315 payments — averaging $28.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$2K
- Novo Nordisk$1K
- GSK$721
- Biohaven Pharmaceutical Holding Company Ltd.$520
- Amgen$519
- AstraZeneca$485
- plus $3K from 27 others
What the payments were for
- Consulting fees$2,19024%
- Travel & lodging$3013%
- Food & beverage$6,52072%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 3 | $2,238 |
| Novo Nordisk | 62 | $1,139 |
| GSK | 31 | $721 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $520 |
| Amgen | 22 | $519 |
| AstraZeneca | 23 | $485 |
| AbbVie(2 entities) | 25 | $456 |
| Biohaven Pharmaceuticals, Inc. | 12 | $402 |
| Pfizer | 19 | $346 |
| Lilly USA, LLC | 15 | $335 |
| Johnson & Johnson(2 entities) | 13 | $323 |
| Abbott | 12 | $259 |
| Merck | 21 | $199 |
| Bayer | 9 | $166 |
| Boehringer Ingelheim | 10 | $160 |
| Inspire Medical Systems, Inc. | 1 | $160 |
| Teva Pharmaceuticals USA, Inc. | 4 | $85 |
| Otsuka America Pharmaceutical, Inc. | 3 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $61 |
| IBSA Pharma Inc. | 3 | $54 |
| Exact Sciences | 3 | $48 |
| Arbor Pharmaceuticals, Inc. | 2 | $42 |
| Amneal Pharmaceuticals LLC | 2 | $39 |
| Neurocrine Biosciences, Inc. | 1 | $28 |
| Boston Scientific | 1 | $20 |
| Eisai Inc. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Medtronic | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$611
- Inspire$160
- BREZTRI$122
- TRELEGY ELLIPTA$120
- AREXVY$117
- LINX Reflux Management System$111
- AIMOVIG$104
How this compares
$9,011 in reported general payments places this provider in the 85th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 62 | $75,790 |
| EliquisApixaban | 46 | $62,728 |
| AustedoDeutetrabenazine | 14 | $58,873 |
| TrulicityDulaglutide | 39 | $57,761 |
| JardianceEmpagliflozin | 44 | $47,952 |
| JanuviaSitagliptin Phosphate | 13 | $14,159 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $13,972 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $8,207 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 15 | $6,302 |
| Rosuvastatin Calcium | 273 | $5,785 |
| Buprenorphine | 13 | $4,702 |
| Losartan Potassium | 301 | $3,930 |
| Levothyroxine Sodium | 322 | $3,543 |
| Atorvastatin Calcium | 328 | $3,469 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $2,868 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,139 | $75,79062 claims |
| PfizerEliquis | $346 | $62,72846 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $85 | $58,87314 claims |
| Lilly USA, LLCTrulicity | $335 | $57,76139 claims |
| Boehringer IngelheimJardiance | $160 | $47,95244 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $721 | $22,17834 claims |
| MerckJanuvia | $199 | $14,15913 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $39 | $3,543322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Franklin
- Kevin DennisFranklin$354K
- Alex SlandzickiFranklin$127K
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Emily HubbsKingsport$2.8M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.